A statement of changes in beneficial ownership filed on September 11, 2026, discloses that Rehan Verjee, a director of Tyra Biosciences, Inc. (NASDAQ:TYRA), purchased shares of the company's common stock on September 9, 2026.

Key Highlights

  • Reporting Person: Rehan Verjee, identified as a director of Tyra Biosciences, Inc.
  • Transaction: Purchase (code P) of 971.8943 shares of common stock on September 9, 2026.
  • Weighted Average Price: $20.5784 per share, with individual transaction prices ranging from $20.5550 to $20.6488.
  • Resulting Ownership: 971.8943 shares of common stock beneficially owned directly following the reported transaction.
  • Multiple Transactions: The shares were purchased across multiple transactions at varying prices within the stated range.

Director Purchase of Tyra Biosciences Common Stock Reported

According to the filing, Rehan Verjee, serving in a director capacity at Tyra Biosciences, Inc., acquired 971.8943 shares of the company's common stock on September 9, 2026. The transaction was recorded with a transaction code of P, indicating an open-market purchase. The filing notes a weighted average price of $20.5784 per share for the acquisition. Tyra Biosciences, Inc. is a biosciences company headquartered at 2656 State Street, Carlsbad, California 92008.

As disclosed in the filing's Explanation of Responses, "the price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $20.5550 to $20.6488." The filing further states that Verjee "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range." The beneficial ownership reported following the transaction is listed as 971.8943 shares held directly.

The filing was signed on September 11, 2026, by Ali D. Fawaz as Attorney-in-Fact on behalf of the reporting person. No derivative securities transactions were reported in Table II of the filing. The filing was submitted as an individual report by one reporting person, and no amendment date was indicated, suggesting this is an original filing.

What Was Disclosed

The filing reports that director Rehan Verjee purchased 971.8943 shares of Tyra Biosciences common stock on September 9, 2026, at a weighted average price of $20.5784, across multiple transactions ranging from $20.5550 to $20.6488 per share.